As EGFRmut NSCLC is uniquely sensitive to EGFR-targeting inhibitors, we hypothesized that targeting MSI2 might influence the efficacy of small molecule EGFR tyrosine kinase inhibitors in these cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.